Skip to content
news
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results...
Oct 10, 2024
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize...
Oct 8, 2024
Lipocine to Host Virtual KOL Event on LPCN 2401 for...
Oct 2, 2024
Company
About Lipocine
Management
Board of Directors
Corporate Governance
Careers
Pipeline & Product
Pipeline
LPCN 1154 – Postpartum Depression
LPCN 2201 – Major Depressive Disorder
LPCN 2101 – Epilepsy
LPCN 2203 – Essential Tremor
LPCN 1148 – Management of Liver Cirrhosis
LPCN 2401 – Obesity Management
LPCN 1107 – Prevention of Preterm Birth
LPCN 1154 – Postpartum Depression
LPCN 2201 – Major Depressive Disorder
LPCN 2101 – Epilepsy
LPCN 2203 – Essential Tremor
LPCN 1148 – Management of Liver Cirrhosis
LPCN 2401 – Obesity Management
LPCN 1107 – Prevention of Preterm Birth
Product
TLANDO®
TLANDO®
Investors/Media
Overview
Press Releases
Events
Presentations
Financials & Filings
Stock Information
Investor FAQs
Contact
Address & Inquiries
Business Development
Linkedin-in
Search
Press
Press
October 10, 2024
October 10, 2024
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
Read More
October 8, 2024
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries
Read More
October 2, 2024
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024
Read More
August 27, 2024
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
Read More
August 8, 2024
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024
Read More
August 6, 2024
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
Read More
June 25, 2024
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study
Read More
June 10, 2024
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024
Read More
May 9, 2024
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
Read More
Innovating beyond
boundaries for patients